8-K current report · filed Sep 1, 2026

ALUMIS INC. (ALMS) 8-K Current Report: September 1, 2026

Item 8.01Item EX-99.1Item EX-99.2ALMS overview

Short answer

ALUMIS INC. (ALMS) filed an 8-K current report with the SEC on September 1, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). September 1, 2026 disclosure covers envudeucitinib Phase 2b LUMUS topline results in systemic lupus erythematosus.

ALUMIS INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • September 1, 2026 disclosure covers envudeucitinib Phase 2b LUMUS topline results in systemic lupus erythematosus
  • Planned NDA submission in fourth quarter 2026 creates a key regulatory catalyst
  • Prespecified subgroup analyses may influence future Phase 3 development and lupus strategy
  • Potential expansion into cutaneous lupus erythematosus and Sjögren’s disease supports a broader TYK2 opportunity
  • Results remain subject to regulatory acceptance, safety, efficacy, replication, funding, and commercialization risks

Item EX-99.1 · Exhibit EX-99.1

  • LUMUS Phase 2b missed primary and secondary endpoints in the overall 408-patient SLE population, weakening near-term lupus prospects
  • Prespecified IFNGS-high subgroup showed robust BICLA, CLASI-50, SRI-4, and LLDAS responses, supporting planned Phase 3 regulatory discussions
  • IFNGS-high patients were under-represented, making overall results less reflective of Alumis’s targeted interferon-driven strategy
  • Dose-dependent interferon-pathway suppression peaked at 40mg twice daily, with no new safety signals
  • Psoriasis remains the nearer-term catalyst, with NDA submission still targeted for 4Q 2026

Item EX-99.2 · Exhibit EX-99.2

  • LUMUS Phase 2b missed primary and secondary endpoints overall, materially weakening envudeucitinib’s broad SLE development case
  • IFNGS-high subgroup showed stronger efficacy, including BICLA response rates of 40.7% to 52.6% versus 28.6% placebo
  • IFNGS-low patients represented 40% of participants, contributing to high placebo response and diluted overall treatment effects
  • Safety remained favorable, with no MACE, extended MACE, or malignancies reported across treatment arms
  • FDA and EMA End-of-Phase 2 meetings planned to determine Phase 3 design, dose, and IFNGS-based enrollment criteria

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ALUMIS INC. 8-K filings

Get the next ALMS 8-K as it lands

Follow ALMS for push alerts, or ask the research agent what this filing means.